15/08/2024
Wafik El-Deiry carted a bunch of books around the Mediterranean. Here are his reviews. Book review by Wafik El-Deiry.
https://cancerletter.com/book-review/20240809_4/
The Cancer Letter
- Home
- The Cancer Letter
The Cancer Letter is an award-winning weekly newsletter covering cancer research funding, legislation Congress and the pharmaceutical industry.
The Cancer Letter, a weekly online publication, is the leading source of information on development of cancer therapies, cancer research funding and health care finance, legislation and policy. The Cancer Letter reaches the key opinion leaders in academic oncology and in the biotechnology and pharmaceutical industries. Our audience includes faculty and staff members at cancer centers, pharmaceutic
al and biotechnology companies, government agencies, and Wall Street professionals. Based in Washington, D.C., The Cancer Letter provides in-depth coverage of events at cancer centers, the National Cancer Institute, National Institutes of Health, Food & Drug Administration, U.S. Over the past four decades, The Cancer Letter has earned acclaim and numerous journalism awards for its investigative coverage of issues that shape oncology. Our work has been profiled and cited in The New York Times, The Washington Post, 60 Minutes, 20/20, CNN, NPR, Science, Nature and many other news outlets. Our coverage has triggered investigations by Congressional committees, the Institute of Medicine, the Federal Trade Commission, the Securities and Exchange Commission, and the Department of Justice. The Cancer Letter was founded in 1973 by journalist Jerry D. Boyd, two years after Congress passed the National Cancer Act of 1971. Boyd retired in 1990, turning over the company to his daughter Kirsten Boyd Goldberg, who served as editor and publisher for the next 20 years. Paul Goldberg became publisher in January 2011.
14/08/2024
Senate Appropriations Committee slates $1.77B increase for National Institutes of Health (NIH), $270M for National Cancer Institute in FY25.
https://cancerletter.com/capitol-hill/20240809_7/
14/08/2024
Why Bernie Fisher deserves a biography (and why I am writing it). Guest editorial by Stacy Wentworth.
https://cancerletter.com/cancer-history-project/20240809_3/
13/08/2024
Rod Nordland’s “Waiting For the Monsoon” reminds us of what our patients face daily. Guest editorial by Leonidas C. Platanias of Lurie Cancer Center.
https://cancerletter.com/book-review/20240809_6/
13/08/2024
What are you reading in 2024? The Cancer Letter’s summer reading list is here and it’s full of titles to help you drive professional growth, reflect on a divided nation—and even explore a little “neural nostalgia” with Beyoncé.
https://cancerletter.com/book-review/20240809_2/
12/08/2024
Why we need the Museum of Medicine and Biomedical Discovery. Guest editorial by Mace Rothenberg.
https://cancerletter.com/guest-editorial/20240809_5/
12/08/2024
“All in Her Head” (by Elizabeth Comen) catalogs the history of medicine’s atrocities against women.
https://cancerletter.com/conversation-with-the-cancer-letter/20240809_1/
08/08/2024
Of adaptive and factorial designs - A biostatistician’s interpretation of last week’s ODAC. Guest editorial by Donald A. Berry.
https://cancerletter.com/trials-and-tribulations/20240802_4/
07/08/2024
How a Georgetown University School of Medicine student found her calling in surgery, law, and health equity.
https://cancerletter.com/conversation-with-the-cancer-letter/20240802_3/
06/08/2024
Georgetown Law-MedStar Health: Patients with cancer can rely on our lawyers to fight legal issues that harm health.
https://cancerletter.com/conversation-with-the-cancer-letter/20240802_2/
05/08/2024
American Cancer Society is using an AI-powered platform in the largest-ever population study of Black women.
https://cancerletter.com/health-equity/20240802_5/
05/08/2024
Solving problems doctors can’t fix: How Georgetown Law/MedStar Georgetown University Hospital's medical-legal partnership saves lives by including lawyers on cancer care teams.
https://cancerletter.com/health-equity/20240802_1/
01/08/2024
Better oncology drug management could lead to improved outcomes, lower costs. Guest editorial by Matt Ingram.
https://cancerletter.com/trials-and-tribulations/20240726_4/
31/07/2024
Tweaking the existing systems is not the answer to drug shortages. Letter to the editor by Fran Visco (National Breast Cancer Coalition).
https://cancerletter.com/letter-to-the-editor/20240726_3/
30/07/2024
Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025.
https://cancerletter.com/news-analysis/20240726_2/
29/07/2024
ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications.
https://cancerletter.com/regulatory-news/20240726_1/
25/07/2024
Cancer Moonshot contributes additional $100M to reduce cancer burden in Africa.
https://cancerletter.com/white-house/20240719_4/
24/07/2024
Want to see what The Cancer Letter is reporting on first? Sign up for our news alerts and get the latest in oncology news right in your inbox, no subscription required.
https://cancerletter.com/news-alerts
24/07/2024
U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data.
https://cancerletter.com/the-cancer-letter/20240719_3/
23/07/2024
A view from the BMT unit on the day a Russian cruise missile hit Kyiv’s Ohmatdyt hospital. Photo credit: Oleksandr Istomin.
https://cancerletter.com/the-cancer-letter/20240719_2/
22/07/2024
Proposed rule by CMS would expand access to cancer treatment at tribal facilities
https://cancerletter.com/health-equity/20240719_5/
22/07/2024
Platinum drugs are off the shortage list, but the underlying problem is unsolved. FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”
https://cancerletter.com/the-cancer-letter/20240719_1/
17/07/2024
“If I’m not dying, I better go live.” Christy Erickson’s cancer diagnosis led to life as a motorcyclist and strongman competitor.
https://cancerhistoryproject.com/article/christy-ericksons-cancer-diagnosis-led-to-life-as-a-motorcyclist-and-strongman-competitor/
16/07/2024
Infections are a major cause of death in patients treated with CAR T-cell therapy.
Meta-analysis focused on causes of death, excluding relapse, recurrence
https://cancerletter.com/conversation-with-the-cancer-letter/20240712_2/
15/07/2024
NCI’s new chief data scientist Warren Kibbe tells us about efforts to get “AI-ready.”
https://cancerletter.com/conversation-with-the-cancer-letter/20240712_1/
11/07/2024
At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago. Guest editorial by Katerina Politi and Roy S. Herbst.
https://cancerletter.com/guest-editorial/20240705_4/
10/07/2024
A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply. Guest editorial by Michael A. Friedman.
Warning: This is not a public health recommendation. Do not implement.
https://cancerletter.com/guest-editorial/20240705_3/
09/07/2024
Georgetown’s Zachary Baron (O'Neill Institute for National and Global Health Law at Georgetown) on the post-Chevron era: We need guardrails about when agency expertise should be cast aside.
https://cancerletter.com/conversation-with-the-cancer-letter/20240705_2/
08/07/2024
Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care.
https://cancerletter.com/judiciary/20240705_1/
04/07/2024
Edward Sondik, electrical engineer turned public health expert and one-time interim NCI director, dies at 82
https://cancerletter.com/obituary/20240628_4/
Address
Telephone
Website
Alerts
Be the first to know and let us send you an email when The Cancer Letter posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Contact The Business
Send a message to The Cancer Letter:
Shortcuts
- Address
- Telephone
- Alerts
- Contact The Business
- Claim ownership or report listing
-
Want your business to be the top-listed Media Company?
Share
